甘氨酰-N-(4-硝基苯基)脯氨酰胺盐酸盐(1:1) | 103213-34-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 甘氨酰-N-(4-硝基苯基)脯氨酰胺盐酸盐(1:1)
• 中文别名: 甘氨酰-脯氨酰-对硝基苯胺盐酸盐；N-甘氨酰脯氨酰-对硝基苯胺盐酸盐；甘氨酰脯氨酸对硝基苯胺
• 英文名称: GP-pNA, Chromogenic Substrate
• 英文别名: 1-(2-aminoacetyl)-N-(4-nitrophenyl)pyrrolidine-2-carboxamide;hydrochloride
• CAS: 103213-34-9
• 化学式: C13H17ClN4O4
• 分子量: 328.75
• InChiKey: VBBFIBMVFSUUBP-UHFFFAOYSA-N

物化性质

• 溶解度：
  DMF：30mg/mL； DMSO：30mg/mL；乙醇：30mg/mL； PBS（pH 7.2）：10 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• WGK Germany：
  3

文献信息

• Pyrrolidinone compounds
  申请人：Eli Lilly and Company

  公开号：US10807971B2

  公开（公告）日：2020-10-20

  The present invention provides compounds which are of the formula (I) and (II) wherein X is selected from the group consisting of (III) and (IV); R is selected from the group consisting of (V) and (VI); Q is selected from the group consisting of (VII) and (VIII); and (IX) R2 is selected from the group consisting of (X) and (XI); or a pharmaceutically acceptable salt thereof, methods for treating obesity, type II diabetes, and compositions.

  本发明提供了式(I)和(II)的化合物，其中X选自(III)和(IV)组成的组；R选自(V)和(VI)组成的组；Q选自(VII)和(VIII)组成的组；以及(IX)R2选自(X)和(XI)组成的组；或其药学上可接受的盐、治疗肥胖症、II型糖尿病的方法和组合物。
• PYRROLIDINONE COMPOUNDS
  申请人：Eli Lilly and Company

  公开号：US20190345144A1

  公开（公告）日：2019-11-14

  The present invention provides compounds which are of the formula (I) and (II) wherein X is selected from the group consisting of (III) and (IV); R is selected from the group consisting of (V) and (VI); Q is selected from the group consisting of (VII) and (VIII); and (IX) R 2 is selected from the group consisting of (X) and (XI); or a pharmaceutically acceptable salt thereof, methods for treating obesity, type II diabetes, and compositions.
• [EN] PYRROLIDINONE COMPOUNDS<br/>[FR] COMPOSÉS PYRROLIDINONE
  申请人：LILLY CO ELI

  公开号：WO2018098781A1

  公开（公告）日：2018-06-07

  The present invention provides compounds which are of the formula (I) and (II), wherein X is selected from the group consisting formula (III), (IV), (V) and (VI); R is selected from the group consisting of formula (VII), (VIII), (IX), (X), (XI) and (XII); Q is selected from the group consisting of formula (XIII), (XIV), (XV) and (XVI) and R2 is selected from the group consisting of formula (XVII), (IX) (X), (XI), and (XII); or a pharmaceutically acceptable salt thereof, methods for treating obesity, type II diabetes, and compositions.